|
Nov. 29, 2004
MEDIA CONTACT: Toni Baker
Media Relations Coordinator
MCG Research and Academics
706-721-4421 Phone
706-723-1401 Beeper
tbaker@mcg.edu
FINDING COULD IMPROVE SAFETY OF STEM CELL TRANSPLANTS
A lipid that helps destroy potentially harmful cells during brain
development shows promise for improving the safety and efficacy of
stem cell transplants, say researchers at the Medical College of Georgia
and University of Georgia.
When embryonic stem cells are being coaxed toward becoming brain
cells that could be transplanted, that lipid, ceramide, helps eliminate
cells that could later form tumors called teratomas, researchers say
in the Nov. 22 issue of The Journal of Cell Biology.
“The body has amazing mechanisms to eliminate cells that are
no longer wanted and that if they remain will harm the body by developing
into tissues that are not meant to be,” says Dr. Erhard Bieberich,
MCG biochemist and the study’s lead author. “Our studies
show this particular mechanism can help stem cells safely become the
cells we want them to be.”
“This is another approach to controlling differentiation and
getting the cell types that you want,” says Dr. Brian G. Condie,
developmental neurobiologist at UGA and MCG and senior author on the
paper.
While it’s the ability of embryonic stem cells to make all
types of tissue – from brain cells to heart cells – that
has scientists worldwide exploring their potential to treat devastating
diseases, their pluripotency can also be harmful if uncontrolled,
says Dr. Bieberich.
Drs. Bieberich and Condie demonstrated in the Aug. 4, 2003 issue
of The Journal of Cell Biology that a natural process occurs
during development to eliminate excessive and potentially harmful
cells. Just before neurons begin forming, there is a massive production
of proteins and up-regulation of lipids. At that point, about half
the cells have high levels of the protein PAR-4, half have high levels
of the protein, nestin, and all have high levels of ceramide.
The researchers found cells that inherited PAR-4 died when partnered
with ceramide. Fortunately, the nestin-bearing cells are most likely
to become neurons while the PAR-4 cells, should they survive, could
contribute to brain malformation.
In this new paper, they took their findings in mouse embryonic stem
cells and also looked at an approved line of human embryonic stem
cells available through the National Institutes of Health Embryonic
Stem Cell Registry.
They found as the cells differentiated in culture, those containing
PAR-4 have yet another bad dance card.
“We have discovered that particular cells derived from embryonic
stem cells that express PAR-4 also cause teratoma formation,” says
Dr. Bieberich of the mostly benign growths comprised of multiple types
of tissue, typically none of which belong in the tissue where they
are found.
They found PAR-4-expressing cells also express Oct-4, a transcription
factor that controls a cell’s ability to develop into all three
basic types of tissue: mesoderm, ectoderm and endoderm. “If
Oct-4 is expressed, the cells are still pluripotent, which is good
if you want to grow all those kinds of embryonic layers,” says
Dr. Bieberich. “But if you transplant them, you are at risk
of forming teratomas.”
However, at least in the culture dish, when they added PAR-4’s
lethal dance partner, ceramide, to the mix, PAR-4- and Oct-4-expressing
cells again died before they could do harm.
The ceramide analogue, N-oleoyl serinol, or S18, also increased
the proportion of nestin-containing cells in cell cultures and grafts.
Drs. Bieberich and Condie were quick to note that in their studies,
they intentionally left PAR-4- and Oct-4-bearing cells in the mix
to see if they could eliminate them.
“There already are ways to grow stem cells, purify them in
cell culture and get a pure population of stem cells that you can
transplant,” says Dr. Condie. “You want to make those
cells differentiate into a particular cell type that is no longer
able to form teratomas,” Dr. Bieberich says of this purification. “Having
said that, that may not always be absolute.”
“What we are trying to do is find ways that can be combined
with those methods currently being used to further reduce the c hances
of teratoma formation and make stem cells extremely safe,” Dr.
Condie says. “This is something that you want to have zero doubt
about.”
The next step is to look at an intact mouse embryo to see if the
identical processes are at work.
The researchers’ work was funded by the NIH’s National Institute
of Neurological Disorders and Stroke . Staff members of Dr. Bieberich’s
lab, Dr. Jeane Silva, research coordinator; Dr. Guanghu Wang, research
associate; and Kannan Krishnamurthy, graduate student; contributed to
this work and co-author the publication. |